Perampanel for Sporadic Amyotrophic Lateral Sclerosis (ALS)

ALS Clinical Trial

Official title:

Perampanel for Sporadic Amyotrophic Lateral Sclerosis (ALS): A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 2 Trials

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03019419
• Other study ID #: A2016-J000-001
• Status: Completed
• Phase: Phase 2
• Start date: April 24, 2017
• Est. completion date: December 23, 2020

Study information

• Verified date: January 2021
• Source: Tokyo Medical University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To investigate the safety and the efficacy of perampanel in patients with sporadic amyotrophic lateral sclerosis

Description:

To evaluate the effect of peramanel for 48 weeks on progression of disease in subjects with ALS, as measured by ALS Functional Rating Scale-Revised (ALSFRS-R)

Recruitment information / eligibility

• Status: Completed
• Enrollment: 66
• Est. completion date: December 23, 2020
• Est. primary completion date: December 23, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years to 78 Years

Eligibility

[Eligibility Criteria for Interim Registration]

• Patients who are able to submit written informed consent. If patients are duly capable of study consent but are unable to sign by themselves due to aggravation of disease condition, written informed consent can be obtained from a legally authorized representative who can sign on behalf of the patients after confirming the patients' agreement to study participation.

• Patients who are male or female aged 40 years to 78 years at the time of obtaining informed consent

• Patients who have clinically definite ALS, clinically probable ALS, or clinically probable-laboratory supported ALS as specified in the revised El Escorial Airlie House diagnostic criteria.

• The sum of the 3 respiratory items of the ALSFRS-R must total 12 points or more

• Patients within 2-year elapsed time period from disease onset at the time of obtaining informed consent

• Patients who can visit study site for out-patient treatment

[Eligibility Criteria for Registration]

Subjects who meet the following criteria in addition to the inclusion criteria for the interim registration

• The progression on score of ALSFRS-R during 12 weeks of observation period must be between -2 and -5

• Patients who has not initiated newly introduced riluzole therapy after starting the observation period. Or those who has not received dose escalation or resumed administration of riluzole therapy after previous down titration or discontinuation

• Patients who has not initiated newly introduced edaravone therapy after starting the observation period

• Patients who are judged to be eligible for continuation of the study by the investigators

[Exclusion Criteria]

• Patients who underwent tracheostomy.

• Patients who experienced non-invasive positive pressure ventilation.

• Patients whose percent-predicted forced vital capacity (%FVC) is =80%.

• Patients with progressive bulbar palsy type.

• Patients with cognitive impairment, severe disease in the renal, cardiovascular, or hematological system.

• Patients with hepatic disease.

• Patients with malignant tumor.

• Pregnant women or women with a possibility of becoming pregnant.

• Patients who participated in another clinical study within 12 weeks before starting the observation period.

• Patients who has initiated perampanel therapy in the past or at present.

• Patients who are judged to be ineligible for study entry by the investigators.

Related Conditions & MeSH terms

• ALS
• Amyotrophic Lateral Sclerosis
• Motor Neuron Disease

Intervention

Drug:
• Perampanel
4mg/d or 8mg/d
• placebo
placebo

Locations

Country	Name	City	State
Japan	Kitasato University East Hospital	Kanagawa
Japan	Kumamoto Saishunso National Hospital	Kumamoto
Japan	Nagoya University Hospital	Nagoya
Japan	Okayama University Hospital	Okayama
Japan	Hokkaido University Hospital	Sapporo
Japan	Tohoku University Hospital	Sendai
Japan	Shiga University of Medical Science Hospital	Shiga
Japan	The University of Tokyo Hospital	Tokyo
Japan	Tokyo Medical University	Tokyo
Japan	Tokyo Metropolitan Neurological Hospital	Tokyo
Japan	University of Tsukuba Hospital	Tsukuba
Japan	Yamaguchi University Hospital	Yamaguchi

Sponsors (1)

Lead Sponsor	Collaborator
Tokyo Medical University

Country where clinical trial is conducted

Japan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in ALS Functional rating scale		48 weeks
Secondary	Change in ALS Functional rating scale		12, 24, 36, and 48 weeks
Secondary	Manual Muscle Test		12, 24, 36, and 48 weeks
Secondary	Percent-predicted forced vital capacity		12, 24, 36, and 48 weeks